Anna Rostedt Punga
Professor vid Institutionen för medicinska vetenskaper; Klinisk neurofysiologi
- Telefon:
- 018-471 49 41
- E-post:
- anna.rostedt.punga@neuro.uu.se
- Besöksadress:
- Rudbecklaboratoriet C11, Dag Hammarsköldsv 20
75237 UPPSALA - Postadress:
- Rudbecklaboratoriet C11, Dag Hammarsköldsv 20
75237 UPPSALA
- Akademiska meriter:
- MD PhD, Docent, överläkare
- CV:
- Ladda ned CV
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Den röda tråden i min forskning är neurofysiologi och framförallt störd signalering mellan nerver och muskler och sjukdomen Myasthenia Gravis (MG), som leder till ökad muskeltrötthet.Vi arbetar med att hitta pålitliga biomarkörer för MG, bland annat så kallade mikroRNA. Genom en ny unik modell där nerv-och muskelceller odlas på ett elektroniskt chip kan vi spåra detaljerade processer i nerv-muskelsignaleringen och hoppas på sikt kunna få bättre sjukdomsförståelse och utveckla nya läkemedel.
Nyckelord
- myasthenia gravis
- neurofysiologi
- neuromuskulär
Biografi
Anna Rostedt Punga studerade läkarprogrammet med inriktning mot forskning vid medicinska fakulteten, Uppsala universitet och redan då började hon med klinisk forskning på den autoimmuna neuromuskulära sjukdomen myasthenia gravis (MG) 1999. Hon tillbringade 3 månader på Duke MG Clinic med Dr Donald Sanders vid stipendium från Myasthenia Gravis Foundation of America. Hon blev färdig läkare 2003 och erhöll läkarlegitimation efter AT-tjänst 2005. Hon disputerade 2007, efter att ha doktorerat vid Institutionen för Neurovetenskap, Uppsala universitet och hennes doktorsavhandling var inriktad mot olika antikroppstyper av MG. Med hjälp av ett postdocstipendium från SSMF genomförde hon en postdoktorperiod med inriktning på preklinisk forskning kring djurmodeller av myasthenia gravis i prof Rüegg´s forskningsgrupp i Basel, Schweiz 2009-2010. Genom sina postdoktorstudier erhöll hon en internationell utmärkelse från German Myasthenia Gravis Foundation (Eberhardt Pfleiderer Prize).
Efter postdocstudierna beviljades hon en klinisk forskartjänst från Vetenskapsrådet i mycket hög konkurrens (beviljandegrad 8%) 2014 och då grundade hon sin egen forskningsgrupp med fokus på studier inom MG och neuromuskulär signalering vid BMC. Hon leder även flera kliniska studier om MG. Forskningen fokuserar på att förbättra diagnostiska och monitoreringsverktyg vid MG, inklusive biomarkörer och neurofysiologi, både in vivo och in -vitro, liksom nya behandlingsalternativ. Hon uppbär flera externa nationella forskningsanslag, bland annat två stycken från Vetenskapsrådet och tilldelades nyligen Göran Gustafssons stora pris i medicin för yngre forskare för hennes studier inom MG. Dr Pungas team har varit pionjärer inom området för microRNA-biomarkörer vid MG och har flera publikationer i detta ämne. Hon har även forskat kring spridningseffekterna i ansiktsmuskler av botulinumtoxin.
Anna Rostedt Punga kombinerar rollen som professor/lärare och forskningsgruppledare med klinisk anställning som överläkare i klinisk neurofysiologi vid Avdelningen för Klinisk Neurofysiologi, Akademiska sjukhuset. Hon har publicerat mer än 50 granskade originalartiklar, samt 8 översiktssartiklar och 2 bokkapitel. Hon har haft 4 doktorander som disputerat med henne som huvudhandledare och en som bihandledare.
Publikationer
Senaste publikationer
- Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls. (2024)
- Generalized myasthenia gravis with acetylcholine receptor antibodies (2024)
- Short-term changes in serum miRNA levels and patient-reported clinical outcomes in myasthenia gravis. (2024)
- Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients (2024)
- Antibody-positive autoimmune encephalitis and paraneoplastic neurological syndrome (2024)
Alla publikationer
Artiklar
- Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls. (2024)
- Generalized myasthenia gravis with acetylcholine receptor antibodies (2024)
- Short-term changes in serum miRNA levels and patient-reported clinical outcomes in myasthenia gravis. (2024)
- Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients (2024)
- Antibody-positive autoimmune encephalitis and paraneoplastic neurological syndrome (2024)
- Pregnancy outcomes for women with myasthenia gravis and their newborns (2024)
- Response to "More evidence is needed for the association between serum myasthenia gravis and adverse pregnancy, delivery and neonatal outcomes" (2024)
- Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome (2023)
- Reply to the Letter to the Editor in response to "Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis (2023)
- Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis (2023)
- Keeping up appearances (2023)
- Implementation of tailored exercise programs for MG patients in a gym setting (2023)
- Towards Personalized Medicine in Myasthenia Gravis (2022)
- Novel pathogenic ALG2 mutation causing congenital myasthenic syndrome (2022)
- Ultrathin Gold Microelectrode Array using Polyelectrolyte Multilayers for Flexible and Transparent Electro-Optical Neural Interfaces (2022)
- Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis The RINOMAX Randomized Clinical Trial (2022)
- Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders (2022)
- Enrichment of serum IgG4 in MuSK myasthenia gravis patients (2022)
- Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients (2021)
- Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies (2021)
- miR-1933-3p is upregulated in skeletal muscles of MuSK+ EAMG mice and affects Impa1 and Mrpl27 (2020)
- Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs (2020)
- Myasthenia gravis patient and physician opinions about immunosuppressant reduction (2020)
- Myasthenia Gravis and Physical Exercise (2020)
- Editorial (2020)
- Botulinum toxin injections associated with suspected myasthenia gravis (2020)
- Flodvåg av långtidssjuka covid-19-patienter väntar (2020)
- Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis (2020)
- Mortality rates and causes of death in Swedish Myasthenia Gravis patients (2020)
- Epidemiology of Myasthenia Gravis in Sweden 2006-2016 (2020)
- Inflammatory and anti-inflammatory markers in plasma (2019)
- Pattern of Habitual Physical Exercise in Myasthenia Gravis Patients (2019)
- Study protocol for a randomised controlled trial with clinical, neurophysiological, laboratory and radiological outcome for surgical versus non-surgical treatment for lumbar spinal stenosis (2019)
- Facing the challenges of electrodiagnostic studies in the very elderly (>80 years) population (2019)
- Cognitive dysfunction in mice with passively induced MuSK antibody seropositive myasthenia gravis (2019)
- miR-30e-5p as predictor of generalization in ocular myasthenia gravis (2019)
- Long-Term High-Density Extracellular Recordings Enable Studies of Muscle Cell Physiology (2018)
- Thymectomy lowers the myasthenia gravis biomarker miR-150-5p (2018)
- Reply to "high abnormal rate in the repetitive nerve stimulation test in acute onset myasthenia gravis" (2018)
- Circulating microRNAs as potential biomarkers in myasthenia gravis patients. (2018)
- Circulating microRNA plasma profile in MuSK plus myasthenia gravis (2018)
- Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis (2018)
- Advances in autoimmune myasthenia gravis management (2018)
- Lifestyle factors and disease-specific differences in subgroups of Swedish Myasthenia Gravis (2018)
- The impact of physical exercise on neuromuscular function in Myasthenia gravis patients (2018)
- Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles (2017)
- Diagnostic Utility of Repetitive Nerve Stimulation in a Large Cohort of Patients With Myasthenia Gravis (2017)
- Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients. (2017)
- High-resistance strength training does not affect nerve cross sectional area – An ultrasound study (2017)
- Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries (2017)
- Physical exercise in Myasthenia Gravis is safe and improves neuromuscular parameters and physical performance-based measures (2017)
- Low vitamin D levels in healthy controls and patients with autoimmune neuromuscular disorders in Greece (2016)
- Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized Myasthenia Gravis (2016)
- Compound Motor Action Potential (2016)
- A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines (2016)
- Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. (2016)
- Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis (2015)
- Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients (2015)
- Regional Diffusion of Botulinum Toxin in Facial Muscles (2015)
- How clinical trials of myasthenia gravis can inform pre-clinical drug development (2015)
- Correlation of Botulinum Toxin Dose with Neurophysiological Parameters of Efficacy and Safety in the Glabellar Muscles (2014)
- Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies (2014)
- Circulating miRNAs in myasthenia gravis (2014)
- Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK plus ) experimental autoimmune Myasthenia gravis (EAMG) (2013)
- beta-glucans reduce LDL cholesterol in patients with myasthenia gravis (2013)
- Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3 (2012)
- Neurophysiological characteristics of MuSK antibody positive Myasthenia Gravis mice (2012)
- Usefulness of assessing repeater F-waves in routine studies (2012)
- Fatigue and Muscle Atrophy in a Mouse Model of Myasthenia Gravis Is Paralleled by Loss of Sarcolemmal nNOS (2012)
- Signaling and aging at the neuromuscular synapse (2012)
- MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity (2011)
- Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice (2011)
- Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate (2009)
- Acetylcholinesterase inhibitors in myasthenia gravis (2009)
- Indication of peripheral nerve hyperexcitability in adult-onset subacute sclerosing panencephalitis (SSPE) (2008)
- Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis (2007)
- Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire (2006)
- Correlation between regional myasthenic weakness and mental aspects of quality of life (2006)
- Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes (2006)
- Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody (2006)
- Validation of the Swedish version of the disease- specific myasthenia gravis questionnaire. (2006)
- Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in myasthenia gravis patients (2005)
- Evaluation of motor unit potential parameters in relation to morphology of skeletal muscles culture on MEA chips
- Evaluation of muscle action potential parameters in relation to morphology of skeletal muscle cell culture on high-density microelectrode array chips
- Clinical and Neurophysiological Outcome of a Randomized Controlled Trial for the Treatment of Lumbal Spinal Stenosis
- Lifestyle factors and gender-related differences in clinical subgroups of Myasthenia Gravis in southern Sweden